Opening of New Boston Facility Focused on Cancer Drug Development and Expansion of Expert Oncology Team
GAITHERSBURG, Md. & BOSTON–(BUSINESS WIRE)–Sensei Biotherapeutics., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the appointment of Robert Pierce, M.D., as chief scientific officer and the opening of its Boston office. Sensei’s facility in Boston will include office space and laboratories for conducting immuno-oncology drug discovery and development, as the company builds an expert team under Dr. Pierce’s leadership focused on developing innovative cancer treatments.